Logo image of COX.PA

NICOX SA (COX.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:COX - FR0013018124 - Common Stock

0.579 EUR
0 (-0.52%)
Last: 4/27/2023, 7:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to COX. COX was compared to 83 industry peers in the Biotechnology industry. COX has a bad profitability rating. Also its financial health evaluation is rather negative. COX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year COX has reported negative net income.
COX had negative earnings in each of the past 5 years.
In the past 5 years COX always reported negative operating cash flow.
COX.PA Yearly Net Income VS EBIT VS OCF VS FCFCOX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

The profitability ratios for COX are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COX.PA Yearly ROA, ROE, ROICCOX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -10 -20 -30 -40 -50

1.3 Margins

COX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COX.PA Yearly Profit, Operating, Gross MarginsCOX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

COX does not have a ROIC to compare to the WACC, probably because it is not profitable.
COX has more shares outstanding than it did 1 year ago.
COX has a worse debt/assets ratio than last year.
COX.PA Yearly Shares OutstandingCOX.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
COX.PA Yearly Total Debt VS Total AssetsCOX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -8.19, we must say that COX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -8.19, COX is not doing good in the industry: 69.14% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.47 indicates that COX is not too dependend on debt financing.
The Debt to Equity ratio of COX (0.47) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Altman-Z -8.19
ROIC/WACCN/A
WACC6.99%
COX.PA Yearly LT Debt VS Equity VS FCFCOX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M 100M

2.3 Liquidity

A Current Ratio of 4.10 indicates that COX has no problem at all paying its short term obligations.
COX's Current ratio of 4.10 is fine compared to the rest of the industry. COX outperforms 75.31% of its industry peers.
COX has a Quick Ratio of 4.10. This indicates that COX is financially healthy and has no problem in meeting its short term obligations.
COX has a better Quick ratio (4.10) than 79.01% of its industry peers.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 4.1
COX.PA Yearly Current Assets VS Current LiabilitesCOX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.58% over the past year.
COX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -54.78%.
The Revenue has been growing slightly by 7.25% on average over the past years.
EPS 1Y (TTM)47.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.55%
Revenue 1Y (TTM)-54.78%
Revenue growth 3Y-21.86%
Revenue growth 5Y7.25%
Sales Q2Q%-68.85%

3.2 Future

COX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.12% yearly.
COX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.81% yearly.
EPS Next Y35.92%
EPS Next 2Y9.12%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.23%
Revenue Next 2Y7.81%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
COX.PA Yearly Revenue VS EstimatesCOX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
COX.PA Yearly EPS VS EstimatesCOX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for COX. In the last year negative earnings were reported.
Also next year COX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COX.PA Price Earnings VS Forward Price EarningsCOX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COX.PA Per share dataCOX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.12%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

COX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NICOX SA

EPA:COX (4/27/2023, 7:00:00 PM)

0.579

0 (-0.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap28.92M
Revenue(TTM)3.27M
Net Income(TTM)-27.76M
Analysts85
Price Target2.91 (402.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-46.73%
PT rev (3m)-46.73%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.92%
EPS NY rev (3m)10.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.25%
Revenue NY rev (3m)1.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.84
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.07
BVpS1.05
TBVpS-0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.1
Quick Ratio 4.1
Altman-Z -8.19
F-Score0
WACC6.99%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.55%
EPS Next Y35.92%
EPS Next 2Y9.12%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-54.78%
Revenue growth 3Y-21.86%
Revenue growth 5Y7.25%
Sales Q2Q%-68.85%
Revenue Next Year16.23%
Revenue Next 2Y7.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

NICOX SA / COX.PA FAQ

What is the ChartMill fundamental rating of NICOX SA (COX.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to COX.PA.


Can you provide the valuation status for NICOX SA?

ChartMill assigns a valuation rating of 3 / 10 to NICOX SA (COX.PA). This can be considered as Overvalued.


How profitable is NICOX SA (COX.PA) stock?

NICOX SA (COX.PA) has a profitability rating of 0 / 10.


How financially healthy is NICOX SA?

The financial health rating of NICOX SA (COX.PA) is 3 / 10.


Can you provide the expected EPS growth for COX stock?

The Earnings per Share (EPS) of NICOX SA (COX.PA) is expected to grow by 35.92% in the next year.